Antibody Cocktails Market

An antibody, also called immunoglobulin, is a protective protein produced by the immune system of the body in response to the presence of a foreign substance, called an antigen. Antigens are a wide range of substances that include disease-causing organisms and toxic materials such as insect venom, bacteria, or viruses. An antibody cocktail is basically a combination or cocktail of two different antibodies. The rationale behind combining two antibodies in a cocktail approach is to minimize mutational viral escape.

Market Dynamics

The increasing adoption of inorganic strategies such as partnerships and agreements by key players in the market is expected to drive the market growth during the forecast period. For instance, in May 2021, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Cipla Inc., a multinational pharmaceutical company, entered into a strategic partnership by which F. Hoffmann-La Roche Ltd., will import its antibody cocktail (Casirivimab and Imdevimab) medication into India, where it will then be marketed and distributed by the Cipla’s distribution network.

Moreover, in August 2020, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Regeneron Pharmaceuticals Inc., a biotechnology company, announced that they had agreed to develop, manufacture, and distribute REGN-COV2, Regeneron’s investigational antiviral antibody cocktail, to people around the globe. This collaboration is expected to increase the supply of REGN-COV2 by at least three and a half times the current capacity, with the potential for even further expansion. As a part of this agreement, Regeneron will be responsible for distributing REGN-COV2 in the U.S. and Roche will distribute it outside the U.S., as a part of this agreement.

Key features of the study:

• This report provides an in-depth analysis of the global antibody cocktails market, and provides market size (US$ million) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antibody cocktails market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Cipla Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc., Celltrion Healthcare Co., Ltd., and Eli Lilly and Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global antibody cocktails market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibody cocktails market

Detailed Segmentation:

• Global Antibody Cocktails Market, By Type:
  • Monovalent Antibody
  • Polyvalent Antibody
• Global Antibody Cocktails Market, By Indication:
  • COVID-19
  • Cancer
  • HIV
• Global Antibody Cocktails Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Antibody Cocktails Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Cipla Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • Zydus Cadila
  • AstraZeneca
  • Aridis Pharmaceuticals Inc.
  • Immunome Inc.
  • Celltrion Healthcare Co., Ltd.
  • Eli Lilly and Company

“*” marked represents similar segmentation in other categories in the respective section.